Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI response accurately reflects the on-label indication for acute migraine treatment in adults and correctly notes that REYVOW is not indicated for preventive treatment. No other specific label claims were evaluated, and no contradictions were introduced.
Category Scores
Accurate Statements
REYVOW is indicated for acute treatment of migraine with or without aura in adults.
INDICATIONS AND USAGE (Section 1)
Unsupported Statements
Contradictions
Low
AI Statement
REYVOW is indicated for preventive treatment of migraine.
Label Reference
Limitations of Use (Section 1) — REYVOW is not indicated for the preventive treatment of migraine.
Important Omissions
No evaluation of dosing limits, second-dose effectiveness, 24-hour maximum, driving impairment warning, CNS depression/8-hour restriction, serotonin syndrome, or medication overuse headache, despite being present in the provided label excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only substantive medication-claim evaluated was the acute-vs-preventive indication, which is correctly represented. Other safety-related label content was not claimed.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
The response did not address any dosing or safety elements from the provided label excerpts.
Suggested Improvement
If the user intends a broader label-alignment check, explicitly map additional claims to the relevant label sections (e.g., dosing/limits, driving impairment guidance, CNS depression cautions, serotonin syndrome risk, and medication overuse headache).